Cyclic dinucleotides for treating conditions associated with sting activity such as cancer

US10604542B2 · kind B2 · utility

Assignee

• Innate Tumor Immunity, Inc. · US

Inventors

• Gary D. Glick · Ann Arbor, US
• Shomir Ghosh · Brookline, US
• Edward J. Olhava · Newton, US
• William R. Roush · West Jupiter, US
• Roger Jones · Llandrindod, GB

Key dates

• Filing date: Jan 11, 2017
• Grant date: Mar 31, 2020
• Expiry date: Jan 11, 2037

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61K2039/505
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

This disclosure features dinucleotide compounds that modulate Stimulator of Interferon Genes (STING) activity, for use for example in the treatment of cancer. This disclosure also features compositions as well as other methods of using and making the same (Formula (A)). A and B are each independently selected from the group consisting of Formulae (i), (ii), (iii), and (iv).